Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,10 +2,9 @@
2	2	(((
3	3	(% class="container" %)
4	4	(((
5		-= //A new tridimensional diagnostic framework for CNS conditions// =
	5	+= Neurodiagnoses =
6	6
7		-This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8		-We aim to create a structured, interpretable, and scalable diagnostic tool.
	7	+This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool.
9	9	)))
10	10	)))
11	11
...	...	@@ -13,72 +13,14 @@
13	13	(((
14	14	(% class="col-xs-12 col-sm-8" %)
15	15	(((
16		-= What is this about and what can I find here? =
	15	+= What can I find here? =
17	17
18		-==== **Overview** ====
	17	+* `/docs`: Documentation and contribution guidelines.
	18	+* `/code`: Machine learning pipelines and scripts.
	19	+* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports.
19	19
20		-The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
	21	+= Who has access? =
21	21
22		-* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
23		-* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24		-* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25		-
26		-This methodology enables:
27		-
28		-* Greater precision in diagnosis.
29		-* Integration of incomplete datasets using AI-driven probabilistic modeling.
30		-* Stratification of patients for personalized treatment.
31		-
32		-==== **Diagnostic Axes** ====
33		-
34		-* (((
35		-**Axis 1: Etiology**
36		-
37		-* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
38		-* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
39		-* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
40		-)))
41		-* (((
42		-**Axis 2: Molecular Markers**
43		-
44		-* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
45		-* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
46		-* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
47		-)))
48		-* (((
49		-**Axis 3: Neuroanatomoclinical**
50		-
51		-* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
52		-* //Examples//: Hippocampal atrophy correlating with memory deficits.
53		-* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
54		-)))
55		-
56		-==== **Case Studies** ====
57		-
58		-1. (((
59		-**Sporadic Alzheimer’s Disease**:
60		-
61		-* Axis 1: Sporadic (ApoE4, poor sleep habits).
62		-* Axis 2: Amyloid-beta plaques, elevated NFL.
63		-* Axis 3: Right hippocampus atrophy (visual memory loss).
64		-)))
65		-1. (((
66		-**Genetic Parkinson’s Disease**:
67		-
68		-* Axis 1: Genetic (LRRK2 mutation).
69		-* Axis 2: Alpha-synuclein aggregation.
70		-* Axis 3: Substantia nigra degeneration (motor dysfunction).
71		-)))
72		-
73		-==== **Applications** ====
74		-
75		-This system enhances:
76		-
77		-* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
78		-* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
79		-
80		-== Who has access? ==
81		-
82	82	We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
83	83
84	84	== How to Contribute: ==
...	...	@@ -86,12 +86,6 @@
86	86	* Access the `/docs` folder for guidelines.
87	87	* Use `/code` for the latest AI pipelines.
88	88	* Share feedback and ideas in the wiki discussion pages.
89		-
90		-== Key Objectives: ==
91		-
92		-* Develop interpretable AI models for diagnosis and progression tracking.
93		-* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
94		-* Foster collaboration among neuroscientists, AI researchers, and clinicians.
95	95	)))
96	96
97	97
...	...	@@ -101,11 +101,11 @@
101	101	{{toc/}}
102	102	{{/box}}
103	103
104		-== Main contents: ==
	39	+== Key Objectives: ==
105	105
106		-* `/docs`: Documentation and contribution guidelines.
107		-* `/code`: Machine learning pipelines and scripts.
108		-* `/data`: Sample datasets for testing.
109		-* `/outputs`: Generated models, visualizations, and reports.
	41	+* Develop interpretable AI models for diagnosis and progression tracking.
	42	+* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
	43	+* Foster collaboration among neuroscientists, AI researchers, and clinicians.
	44	+
110	110	)))
111	111	)))